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Abstract 
BACKGROUND: The aim was to examine the effects of high-cocoa polyphenol-rich chocolate on 
lipid profiles, weight, blood pressure, glycemic control, and inflammation in individuals with 
Type 2 diabetes and hypertension. 
METHODS: Sixty individuals [32 in dark chocolate group (DCG) and 28 in white chocolate group 
(WCG)] with Type 2 diabetes on stable medication were enrolled in a randomized, placebo-
controlled double-blind study. Subjects were randomized to consume 25 g DCG or WCG for 8 
weeks. Changes in weight, blood pressure, glycemic control, lipid profile, and high sensitive C-
reactive protein (hsCRP) were measured at the beginning and end of the intervention. This 
clinical trial was registered at the Iranian registry of clinical trials. 
RESULTS: In DCC group, compared with baseline, serum levels of Apo A-1 (P = 0.045) was 
increased and fasting blood sugar (FBS) (P = 0.027), hemoglobin A1c (HbA1c) (P = 0.025), Apo B 
(P = 0.012) and Log of hsCRP (P = 0.043) levels were decreased at the end of study. No changes 
were seen within the WCG in studied parameters. High polyphenol chocolate consumption 
compared to white chocolate resulted in significant decrease in of systolic (−5.93 ± 6.25 vs. −1.07 
± 7.97 mmHg, P = 0.004) and diastolic blood pressure (−6.4 ± 6.25 vs. 0.17 ± 7.9 mmHg, P = 
0.002), FBS (−7.84 ± 19.15 vs. 4.00 ± 20.58 mg/dl, P = 0.019) over the course of 8 weeks of daily 
chocolate consumption neither weight nor body mass index and TG levels altered from baseline. 
CONCLUSION: High polyphenol chocolate is effective in improving TG levels in hypertensive 
patients with diabetes and decreasing blood pressure and FBS without affecting weight, 
inflammatory markers, insulin resistance or glycemic control. 
 
Keywords: Chocolate, Polyphenols, Type 2 Diabetes, Cardiovascular Risk, Lipid Profile, High 
Density Lipoprotein Cholesterol, Apolipoprotein 
 
Date of submission: 4 Feb 2014, Date of acceptance: 18 Oct 2014 
 
Introduction 
The prevalence of Type 2 diabetes mellitus is rising 
worldwide, accompanied by an increasing risk of 
hypertension, cardiovascular disease, and mortality.1 
According to the result of the recent survey on the risk 
factor of chronic disorders in Iran, indicated that 7.8% 
of adult with age 25-64 years have Type 2 diabetes 
mellitus.2 In diabetes, hypertension (defined as a blood 
pressure ≥ 140/90 mmHg) is a common comorbid 
condition affecting ∼20-60% of diabetic patients, 
depending on obesity, ethnicity, and age. In 
observational studies, patients with both diabetes and 
hypertension have approximately twice the risk of 
cardiovascular disease as nondiabetic patients with 
hypertension. Patients with diabetes and hypertension 
have also increased the risk of specific complications, 
including retinopathy and nephropathy.3 
Intense pharmacologic treatment regimens are 
necessary, but often remain inadequate to prevent 
incidence and complications of Type 2 diabetes 
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mellitus.4 Observational studies have shown that 
physical activity, weight loss, and diet can prevent 
diabetes and its complications.4 
Diet is a major lifestyle factor that can greatly 
influence the incidence and the progression of 
chronic diseases such as cancer, cardiovascular 
disease, and diabetes.1 Recently, flavanols, a 
subgroup of plant-derived phytochemicals called 
flavonoids, have gained increasing attention, 
because epidemiological investigations revealed an 
inverse correlation between the dietary intake of 
flavanols and the mortality of cardiovascular 
disease,5 and the incidence of diabetes.6 In the 
context of human nutrition, flavanols are found in 
fruit, vegetables, tea and red wine and especially 
with high concentrations can be present in cocoa 
and cocoa products.7 Dietary interventions with 
flavanol-containing cocoa products in humans 
indicate beneficial effects of flavanols on low-
density lipoprotein oxidation,8 platelet aggregation,9 
insulin sensitivity,10 endothelial function and blood 
pressure.11 
It has been hypothesized that flavonoid 
compounds found in foods, including epicatechin 
found in high-cocoa-solid chocolates, decrease the 
risk of death from coronary heart disease, cancer 
and stroke.12 Short-term administration of dark 
chocolate was followed by a significant increase in 
insulin sensitivity and a decrease in blood pressure 
in healthy subjects.13 Therefore, we hypothesized 
that daily consumption of chocolate (25 g daily) 
containing polyphenol-rich; high-cocoa solids for 8 
weeks would improve cardiovascular risk factors in 
patients with diabetes and hypertension. 
Materials and Methods 
This randomized, placebo-controlled, double-blind 
study was undertaken in the endocrinology and 
metabolism Institute of Tehran University of Medical 
Sciences, Iran, located at Firoozgar Hospital and the 
study was funded by the Tehran University of 
Medical Sciences. The study was approved by the 
Tehran University Ethics Committee, and written 
consent was obtained from all subjects prior to 
enrollment. 
This study was conducted on 35-70 years old 
patients with diabetes and hypertension Type 2 
referred to Firoozgar Hospital from March 2011 to 
February 2012. Sixty-eight subjects [4 in dark 
chocolate group (DCG) and 34 in white chocolate 
group (WCG)] with established Type 2 diabetes (age 
for DCG = 58.71 ± 9.07 and for WCG = 57.17± 
7.86 years) were enrolled by blocked randomization 
method. During the study 2 cases because of insulin 
use in DCG and 6 cases from WCG because of 
insulin use (n = 2) and other supplement 
consumption (n = 4) were excluded. Whom 60 
patients (32 in DCG and 28 in WCG) completed 
the study. The mean diagnosis duration of diabetes 
was (mean ± standard deviation for DCG = 7.46 ± 
4.62 and for WCG = 7.92 ± 3.92) months. 
Inclusion criteria were diagnosis of Type 2 diabetes 
based on the World Health Organization guidelines 
[fasting blood sugar (FBS) > 126 mg/dl or 2h BS > 
200 mg/dl]14 and systolic blood pressure ≥ 140 and 
diastolic blood pressure ≥ 90.15 Exclusion criteria 
included hemoglobin A1c (HbA1c) > 9.0%, 
treatment with insulin, any change in use of 
medication in the previous 2 months, having any 
kind of special diets such as vegetarian, lactation, 
pregnancy, congestive heart failure, malignancies, 
chronic kidney disease, severe cardiac arrhythmias 
and inflammation. All participants were either life-
long nonsmokers or reported smoking abstinence 
of at least 5 years before study inclusion. All of the 
subject’s chronic medications such as lipid reducing 
and blood pressure reducing drugs were maintained 
at stable doses for at least 2 months prior to the 
start of the study. The subjects were given chocolate 
bars containing either dark chocolate or white 
chocolate in the same package by blind person. The 
chocolates delivered as a monthly manner and 
compliance were assessed by asking for how many 
of the chocolate bars were used. Individual’s 
adherence after 8 weeks intervention was 
determined by total chocolate number to consumed 
chocolate. The individuals with < 80% 
consumption were excluded. Subjects were advised 
not to consume any other chocolate during the 
period of the study. In addition, subjects were 
instructed to make no further changes to their diet, 
lifestyle, and physical activity. Flow of participants 
through each stage of the study is available in figure 1. 
The chocolate for the study was provided by 
Farmand Co. The active product was high-
polyphenol chocolate containing 83% cocoa solids 
compared with iso-caloric white chocolate, and was 
packaged to the same color and shape as high 
polyphenol chocolate. 25 g foil-wrapped bars were 
provided individually, and subjects were asked to 
consume one bar every day. Chocolate bars in the 
aluminum foil administered in dated, sequentially 
numbered, nontransparent boxes not labeled about 
content. Involved physicians and staff were unaware 
of the group assignment. Patients did not receive 
information regarding the chocolate and were 
instructed not to disclose their assigned group to 
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investigators. To avoid changes in body weight 
during the intervention, participants were carefully 
instructed how to make proportional reductions in 
energy from their habitual diet to substitute for that 
supplied by chocolates. This amount of dark 
chocolate would provide a total of 143 kcal daily, 
with 450 mg flavonoids in comparison with the 
same amount of calories without flavonoids in 
white chocolate. 
Weight was measured in fasting state using 
calibrated weighing scales in light clothing and bare 
feet with nearest of 0.1 kg. Height was measured by 
un-stretched tape with the nearest of 0.5 cm 
without shoes and standing position near to the 
wall. Body mass index (BMI) was calculated as the 
weight (kg) divided by height (m2). 
To obtain information about dietary intake and to 
confidence none change calorie consumption in 
baseline and endpoint of study, participants were 
asked to 24 h record dietary intakes using 3 days 
dietary records (one for weekend and 2 for week days) 
in the baseline and end of the study. Dietary intake 
data was processed using Nutritionist IV software 
(First Databank, San Bruno, Calif., USA) modified for 
Iranian food. International Physical Activity 
Questionnaire was used for evaluating physical activity 
levels before and after of the study. 10 ml fasting 
venous blood samples were separated by 
centrifugation at 3000 g and stored at -80 °C. Systolic 
and diastolic blood pressure was reported on average 
of two properly measured in the right or left arm 
supported at the heart level of seated position after 10 
min of rest by a trained nurse using a mercury 
sphygmomanometer (Model Gamma G-7; Heine).16 
Fasting plasma glucose was measured by the glucose 
oxidize method (Pars Azmoon kit). HbA1c was 
measured by high-performance liquid chromatography 
method (Menarini Diagnostics, Florence, Italy). Insulin 
was measured by immunoradiometric assay (IRMA) 
method (Immunotech Co. Kit). Serum concentrations 
 
 
 
 
 
 
 
 
 
 
Figure 1. Study participants flow chart 
 
Assessed for eligibility 
(n = 80) 
Excluded (n = 12) 
- Not meeting inclusion criteria (n = 4) 
- Refused to participate (n = 8) 
Randomized 
(n = 68) 
Allocated to White chocolate 
group (WCG) 
(n = 34) 
 
Allocated to Dark chocolate 
group (DCG) 
(n = 34) 
Lost to follow up (n = 6) 
- Insulin use (n = 2) 
- Supplementation use (n = 4) 
Lost to follow up (n = 2) 
- Insulin use (n = 2) 
 
Analyzed (n = 32) 
 
Analyzed (n = 28) 
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of Triglyceride and total cholesterol were measured 
using the GPO-PAP kit and the CHOD-PAP kit, 
respectively (Pars Azmoon kit). High-density 
lipoprotein (HDL) cholesterol was measured by a 
direct colorimetric enzymatic method (Greiner). 
Low-density lipoprotein (LDL) cholesterol was 
calculated by the Friedewald formula. (TG levels of 
all patients were under 400 mg/dl). Apo-
lipoproteins AI and B were measured by 
immunoturbidimetry method by using auto-analyzer 
Cobas (Pars Azmoon kit) and highly sensitive C-
reactive protein (hsCRP) is measured by particle 
enhanced turbid metric immunoassay (Roche 
Products, Germany). 
We used Kolmongrov-Smirnove test for normal 
distribution assessment of data. Normally 
distributed data within groups were compared using 
paired-samples t-test and between groups by 
independent-samples t-test. Log of non-normally 
distributed variables was used for changing their 
distribution to normal. Continues data are presented 
as mean ± standard deviation. Discrete variables are 
presented as n (%) and compared between two 
groups using chi-square test. Data adjusted for age, 
sex, energy intake and ANCOVA test used for 
comparing means between intervention groups. We 
used the SPSS software (version 17.0, SPSS Inc., 
Chicago, IL, USA) for all the statistical analyzes.  
P < 0.050 was considered significant. 
Results 
As shown in table 1, baseline characteristics of the 
participants did not differ between DCG and WCG. 
At the baseline of the study, comparison of dietary 
intakes of energy, carbohydrate, protein, fat, fiber and 
micronutrients including vitamin C, vitamin E, vitamin 
A, selenium and zinc showed no significant differences 
between two groups. Also, within group differences of 
dietary intake were not significant. Thus, there is not 
confounder at the baseline (Table 2).  
 
Table 1. Clinical baseline characteristics of the study population* 
Variable DCG (n = 32) WCG (n = 28) P 
Age (year) 58.71 ± 9.07 57.17 ± 7.86 0.650 
Weight (kg) 77.62 ± 11.40 76.58 ± 11.33 0.770 
Gender    
Men (%) 37.50 (n = 12) 42.90 (n = 12) 0.200† 
BMI (kg.m2) 30.12 ± 4.18 29.42 ± 4.58 0.540 
Duration of diabetes 7.46 ± 4.62 7.92 ± 3.92 0.360 
P values refer to comparisons mean between groups (Independent t-test); * Data are means ± SD or percentage; † Chi-square test used 
for comparing; DCG: Dark chocolate group; WCG: White chocolate group; SD: Standard deviation; BMI: Body mass index 
 
Table 2. Baseline and after intervention energy and selected nutrient intake of participants assigned to dark chocolate 
group (DCG) and white chocolate group (WCG) 
Diet ingredient Intervention group 
Before  
(mean ± SD) 
After  
(mean ± SD) 
Mean difference 
(mean ± SD) P 
Energy (Calories) DCG 1880.80 ± 495.93 1844.72 ± 51.18 -36.290 ± 327.33 0.120 WCG 1981.01 ± 504.61 1923.03 ± 468.72 -57.980 ± 364.88 
Carbohydrate (g) DCG 255.60 ± 72.58 253.20 ± 76.15 -2.400 ± 66.34 0.430 WCG 264.45 ± 81.50 258.87 ± 76.60 -5.570 ± 84.67 
Protein (g) DCG 81.33 ± 26.46 78.47 ± 26.63 -2.860 ± 19.12 0.320 WCG 90.10 ± 40.14 81.28 ± 21.01 -8.820 ± 43.26 
Fat (g) DCG 62.48 ± 24.95 60.69 ± 21.95 -1.780 ± 23.56 0.560 WCG 69.75 ± 27.17 66.85 ± 25.82 -2.900 ± 34.86 
Fiber (g) DCG 12.21 ± 5.92 13.32 ± 5.82 1.110 ± 7.68 0.540 WCG 14.90 ± 11.71 15.02 ± 6.19 2.640 ± 14.04 
Vitamin A (micro g) DCG 945.27 ± 742.54 980.10 ± 704.38 34.830 ± 695.50 0.430 WCG 1067.98 ± 800.76 1022.31 ± 709.27 -45.670 ± 840.37 
Vitamin C (mg) DCG 87.59 ± 83.30 93.57 ± 85.47 5.980 ± 114.69 0.320 WCG 92.65 ± 73.37 87.02 ± 85.71 -5.620 ± 14.01 
Vitamin E (mg) DCG 33.07 ± 63.19 29.82 ± 57.34 -3.240 ± 78.19 0.410 WCG 43.13 ± 84.22 43.03 ± 82.74 -0.090±123.27 
Zinc (mg) DCG 7.89 ± 4.06 7.78 ± 2.98 -0.100 ± 3.69 0.320 WCG 9.26 ± 4.66 8.39 ± 3.03 -0.870 ± 5.91 
Selenium (mg) DCG 0.10 ± 0.05 0.10 ± 0.05 0.004 ± 0.06 0.340 WCG 0.11 ± 0.05 0.12 ± 0.05 0.008 ± 0.08 
P values refer to comparisons mean difference between intervention groups (Independent t-test); SD: Standard deviation; DCG: Dark 
chocolate group; WCG: White chocolate group  
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Table 3 shows the fasting plasma glucose 
concentrations, HbA1c, serum lipids and other 
biochemical variables and the corresponding 
differences of these variables for the WCG and 
DCG. Compared to baseline, consumption of dark 
chocolate resulted in a significant decrease in fasting 
blood glucose (FBG) (-7.84 ± 19.15 mg/dl,  
P = 0.027), diastolic blood pressure (-5.93 ± 6.25 
mmHg, P = 0.001), systolic blood pressure  
(-6.4 ± 6.25 mmHg, P = 0.001), HbA1c  
(-0.14 ± 0.34%, P = 0.025), Apolipoprotein B  
(-4.46 ± 9.44 mg/dl, P = 0.012) and hsCRP levels  
(-7.88 ± 17.98 nm/l, P = 0.043) and significant 
increase in Apo-lipoprotein A-1 level (4.56 ± 12.36 
mg/dl, P = 0.045) in DCG. Despite major changes 
in mentioned variables, no such effects were 
observed in the WCG. Comparison of the two 
intervention groups showed that dark chocolate 
intake resulted in significant decrease in diastolic 
blood pressure (-5.93 ± 6.25 vs. -1.07 ± 7.97 
mmHg, P = 0.002), systolic blood pressure  
(-6.4 ± 6.25 vs. 0.17 ± 7.99 mmHg, P = 0.004), FBS 
(-7.84 ± 19.15 vs. 4.00 ± 20.58 mg/dl, P = 0.019) 
compared to white chocolate consumption. We did 
not observe any significant effect of dark chocolate 
consumption on fasting insulin, HbA1c, triglyceride, 
LDL-cholesterol, HDL-cholesterol, Apo-
lipoproteins AI and Apo-lipoproteins B levels 
comparing to white chocolate consumption. 
 
Discussion 
Cocoa has been claimed to protect the vascular 
endothelium by augmenting nitric oxide (NO) 
availability and thereby improving Endothelium-
dependent vasorelaxation.17 The results of our study 
showed that high cocoa chocolate consumption 
decreased blood pressure among diabetic patients. 
We did not observe any significant effect of dark 
chocolate intake on serum triglyceride, FBG, fasting 
insulin, HbA1c, Apo-lipoprotein B, hsCRP and 
Apo-lipoprotein A-1 level compared to the WCG. 
Also, dark chocolate consumption did not affect 
triglyceride, total cholesterol, HDL-cholesterol and 
LDL-cholesterol levels in comparing with WCG. 
The low cardiovascular mortality observed in 
Kuna Indians has been hypothesized to be 
consequences of high consumption of cocoa-rich 
beverages.18 Studies showed that flavanols, subclass 
of flavonoids is richly represented in natural cocoa 
beans, increased NO production in cultured human 
vascular endothelial cells19 and improved NO 
depended endothelium vaso relaxation in finger and 
brachial arteries of healthy humans.20 Because insulin 
sensitivity is dependent on NO availability, we 
hypothesized that dark chocolate containing 
polyphenols in addition to the decreasing effect on 
blood pressure, it might improve insulin sensitivity.21 
To best of our knowledge, our study was the 
first study done on the diabetic patients with 
hypertension. Results of our study showed that 
feeding of high-polyphenol chocolate for 8 weeks 
decreased systolic and diastolic blood pressure. A 
previous report from a prospective study showed a 
significant inverse relationship between total 
flavonoid intake and coronary heart disease 
mortality over a 5 years follow-up period in elderly 
men.22 Similarly, the Stockholm Heart 
Epidemiology Program, assessing the long-term 
chocolate effects among patients with established 
coronary heart disease, showed that chocolate 
consumption had a strong inverse association with 
cardiac mortality.23 
Previous studies have suggested that 
polyphenols could show lipid-lowering effects 
through different mechanisms including; slowing 
triacylglycerol absorption via pancreatic lipase 
inhibitors, increasing fecal excretion of 
cholesterol,24 decreasing of hepatic B100 secretion25 
and activation of AMP-activated protein kinase.26 
The common lipid abnormality in diabetes 
mellitus is change in plasma triglyceride levels which 
certainly contribute to the development of 
cardiovascular disease.27 
In insulin-deficient diabetic rats, lipoprotein 
lipase is not activated and hypertriglyceridemia was 
happened, Mokhtar Ruzaidi et al.28 Suggested that 
the chocolate extract increased insulin secretion and 
hypotriglyceridemic effect of chocolate extract is 
due to an increase in insulin secretion. 
In the agreement to our study, results of Mellor  
et al. showed that high polyphenol chocolate did not 
have a significant effect on TG level compared with 
low polyphenol in diabetic patients.29 
In other study, daily consumption of dark 
chocolate did not show a significant effect on TG 
compared with consumption of white chocolate in 
healthy subjects.17 It seems that the dark chocolate 
has not hypotriglyceridemic impact in diabetic 
patients and this effect also was not observed in 
healthy subjects. Inconsistent with our findings, two 
other studies13,17 did not observe the effect of 
chocolate consumption on lipid profiles. In our 
study, lipid profiles of subjects did not change 
adversely following the intervention. Thus, the stearic 
acid in cocoa butter may be an explanation for neuter 
the beneficial effects of chocolate consumption. 
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Table 3. Biochemical and anthropometric measurements and mean differences ± standard deviation (SD) at baseline and after the intervention period 
 DCG (n = 32) WCG (n = 28) P** 
Before After Differences P* Before After Differences P* 
Diastolic blood pressure (mmHg) 85.15 ± 8.56 79.21 ± 8.89 -5.93 ± 6.25 0.001 86.96 ± 8.08 87.14 ± 8.09 -1.07 ± 7.97 0.920 0.002 
Systolic blood pressure (mmHg) 137.03 ± 10.61 130.62 ± 11.19 -6.40 ± 6.25 0.001 137.32 ± 8.55 136.25 ± 8.34 0.17 ± 7.99 0.470 0.004 
FBS (mg/dl) 138.06 ± 26.99 130.21 ± 23.67 -7.84 ± 19.15 0.027 134.89 ± 34.46 138.89 ± 30.04 4.00 ± 20.58 0.312 0.019 
Fasting insulin 9.77 ± 6.29 9.36 ± 4.70 -0.40 ± 4.68 0.625 10.37 ± 4.63 11.45 ± 5.98 1.04 ± 6.19 0.572 0.141 
HbA1c (%) 7.24 ± 1.02 7.10 ± 0.83 -0.14 ± 0.34 0.025 7.55 ± 0.94 7.45 ± 1.19 -0.10 ± 0.78 0.504 0.552 
Triglyceride (mg/dl) 118.84 ± 46.02 112.37 ± 41.65 -6.46 ± 19.91 0.110 140.57 ± 47.94 143.57 ± 44.07 3.00 ± 17.82 0.331 0.055 
Total cholesterol (mg/dl) 155.65 ± 35.23 153.15 ± 31.35 -2.50 ± 15.55 0.370 158.64 ± 40.33 152.42 ± 37.49 -6.21 ± 19.49 0.103 0.454 
LDL cholesterol (mg/dl) 90.59 ± 29.31 87.53 ± 22.44 -3.06 ± 20.56 0.406 95.03 ± 38.75 94.35 ± 35.02 -0.67 ± 9.52 0.709 0.340 
HDL cholesterol (mg/dl) 41.87 ± 8.73 42.21 ± 9.17 0.34 ± 7.66 0.802 38.53 ± 9.24 38.57 ± 8.00 0.03 ± 4.63 0.968 0.414 
Apo-lipoproteins AI (mg/dl) 149.81 ± 17.89 154.37 ± 16.02 4.56 ± 12.36 0.045 152.14 ± 25.61 150.46 ± 25.56 -1.67 ± 12.19 0.472 0.060 
Apo-lipoproteins B (mg/dl) 86.53 ± 20.11 82.06 ± 17.94 -4.46 ± 9.44 0.012 87.96 ± 23.79 85.46 ± 21.05 -2.50 ± 11.70 0.268 0.354 
hsCRP (nm/l) 26.71 ± 34.66 18.82 ± 23.72 -7.88 ± 17.98 0.043 18.59 ± 20.70 17.21 ± 15.53 -1.38 ± 14.90 0.831 0.276 
DCG: Dark chocolate group; WCG: White chocolate group; FBS: Fasting blood glucose; HbA1c: Hemoglobin A1c; LDL: Low-density lipoprotein; HDL: High-density lipoprotein; hsCRP: 
Highly sensitive C-reactive protein; Data adjusted for age, sex, energy intake; * Values refer to variation from week 0 to week 8 within groups (Paired t-test); ** Values refer to comparisons 
between groups with adjusting for age, sex, energy intake (ANCOVA test) 
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Unlike some proposed mechanisms for glucose 
lowering effect of polyphenols including; synthesis 
of glucose transporter isoform 1 and activation of 
phosphatidylinositol 3-kinase,17 the results of our 
study indicate that dark chocolate with 450 mg of 
polyphenols is not effective on improvement of 
FBG, insulin and HbA1c levels in hypertensive 
diabetic subjects. Similarly, Mellor et al. did not 
observe a significant effect of polyphenols-rich 
chocolate consumption on fasting glucose, and 
insulin levels.29 
In other study, daily consumption of dark 
chocolate (6.3 g) for 18 weeks, did not 
demonstrate significant improvement in glucose 
and insulin levels. 
In contrast to our findings, consumption of 
flavones (902 mg) for 12 weeks resulted in a 
decrease of insulin resistance in overweight and 
obese subjects.30 Together, regarding these findings, 
we suggest that a higher dose of polyphenols with 
longer duration may result in a reduction of glucose 
and insulin. 
To the best of our knowledge, there are few data 
about anti-inflammatory property of DCG. We 
examined the effect of cocoa consumption on 
hsCRP as an inflammatory marker. 
In our study, despite significant decrease of 
hsCRP within DCG, we did not observe a 
significant difference between dark and WCGs. 
Similar to our findings, the study by Mathur et al. 
showed that cocoa consumption (36.9 g of dark 
chocolate bar and 30.95 g of cocoa powder drink) 
for 6 wk did not affect hsCRP level.31 
There were a few limitations in the present 
study. First, serum polyphenols concentrations were 
not measured at the baseline and end point that may 
affect the results in both groups. In addition, our 
study design has not the possibility to double 
blinding, and patients were aware of the 
intervention grouping kind. Another limitation 
might be the financial restrictions that unpowered 
the follow-up time and more biochemical 
assessments such as polyphenol levels, that may 
need more time and investigation to show 
maximum results on changes in principle outcomes 
measured. Moreover, monitoring adherence to the 
intervention monthly may be another limitation in 
the present study; a close supervision of all 
participants has to be carried out through personal 
contact daily or weekly. Finally, we find that may be 
better this study conducted again with one more 
group as placebo to compare with previous groups 
(DCG and WCG) to provide better controlling. 
Conclusion 
Consuming high-polyphenol chocolate and not 
white chocolate over an 8 weeks period improved 
cardiovascular risk indices by decreasing systolic 
and diastolic blood pressure in patients with 
diabetes and hypertension without a detrimental 
effect on triglyceride, weight, insulin resistance, 
BMI. Our study clearly establishes improvements 
of blood pressure after regular consumption of 
flavanol-containing cocoa in patients with Type 2 
diabetes, highlighting the potential of flavanol-
containing diets, and underscoring their potential 
health care benefit for reducing the risk of 
cardiovascular events in diabetic patients. 
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